FINWIRES · TerminalLIVE
FINWIRES

$JAZZ

25 stories mentioning JAZZUpdated 2d ago

Every FINWIRES story that references JAZZ, newest first.

What are analysts saying about JAZZ?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on JAZZ?

Wire

Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says

Jazz Pharmaceuticals (JAZZ) could see long-term value from Ziihera's pursuit of additional indications such as breast cancer, colorectal and lung, as the therapy moves beyond gastroesophageal adenocarcinoma, UBS said in a Friday note.Ziihera is relatively de-risked in first-line colorectal cancer treatment given its established potency and encouraging proof of concept data, according to the note. UBS said that the current standard of care leaves room for improvement and that there are no approved HER2-targeted therapies in first-line metastatic colorectal cancer.Regarding non-small cell lung cancer, UBS said that while there is limited proof of concept data for Ziihera, preliminary data points toward efficacy.UBS now expects peak Ziihera sales of $3.8 billion from $3.1 billion prior, layering in revenue from colorectal cancer, non-small cell lung cancer and raising gastroesophageal adenocarcinoma probability of success to 100% from 95% previously.UBS raised its price target to $337 from $315 and maintained its buy rating.JAZZ shares were up 2.3% in Friday afternoon trading.Price: $245.98, Change: $+5.50, Percent Change: +2.29%

$JAZZ
Insider Trading

Jazz Pharmaceuticals Insider Sold Shares Worth $19,207,098, According to a Recent SEC Filing

Robert Iannone, Executive Vice President, Global Head of Research and Development and Chief Medical Officer, on August 27, 2026, sold 76,921 shares in Jazz Pharmaceuticals (JAZZ) for $19,207,098. Following the Form 4 filing with the SEC, Iannone has control over a total of 65,686 ordinary shares of the company, with 65,686 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1232524/000173732926000016/xslF345X05/edgardoc.xml

$JAZZ
Wire

Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says

Jazz Pharmaceuticals' (JAZZ) shares are up about 45% year to date, but may still have the potential for moderate further appreciation, RBC Capital Markets said in a note Friday.As the company gradually enters a "more fulsome biotech era," its shares will likely "continue to re-rate, driven by higher-growth opportunities" like the one offered by its cancer drug Ziihera, the note said.RBC said that while some cash flow analyses may indicate that the company's shares are fairly valued, it believes that the stock may see more upside, which would take it closer in line with biotech firms, due to its "ongoing momentum, still relatively undemanding multiple, and further balance sheet optionality."The investment firm also said that it is now more accurately reflecting the value of Jazz's cancer drug Ziihera by including the drug's "pan-tumor potential," which RBC believes may contribute about $500 million by 2035, as well as modeling a recent financing.RBC has an outperform rating on Jazz and lifted the company's price target to $299 from $277.Price: $246.55, Change: $-4.55, Percent Change: -1.81%

$JAZZ
Wire

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

The US Food and Drug Administration has approved usage of Roche's diagnostics tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma patients who may be eligible for treatment with Jazz Pharmaceuticals' (JAZZ) Ziihera, Roche said Wednesday.Roche further said that two Ziihera-containing regimens are now FDA approved for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive GEA.Shares of Jazz Pharmaceuticals were down 4.3% in Wednesday trading.Price: $250.04, Change: $-10.19, Percent Change: -3.92%

$JAZZ
Sectors

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) declining by 0.5%.Boston Scientific (BSX) has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.Jazz Pharmaceuticals' (JAZZ) wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.Summit Therapeutics (SMMT) partner Akeso reported "positive" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.

$BSX$IBB$JAZZ$SMMT$XLV
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In sector news, the US Department of Health and Human Services is planning to create two deputy commissioner roles at the Food and Drug Administration to focus on technology and drugs, respectively, CNBC reported Tuesday. Specifically, the technology deputy commissioner role would focus on the intersection of health and AI, the report said. HHS officials would appoint the new deputies in what some within the Trump administration view as an attempt to wield greater influence over the agency, CNBC reported.In corporate news, McKesson (MCK) agreed to buy Precision Medicine Group for $2.25 billion as part of the drug distributor's efforts to boost its clinical research and commercialization services. McKesson shares rose 3.1%.Anavex Life Sciences (AVXL) shares surged 14% after the company's fiscal Q3 swung to profits.Kura Oncology (KURA) shares jumped past 9% in Tuesday trading, a day after a regulatory filing showed CEO Troy Wilson purchased 100,000 shares at a weighted average price of $12.39.Jazz Pharmaceuticals (JAZZ) shares added 1.8% after the company said the US Food and Drug Administration approved two of its Ziihera-containing regimens to treat adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of cancer.

$AVXL$JAZZ$KURA$MCK
Sectors

Sector Update: Healthcare Stocks Advance Tuesday Afternoon

Healthcare stocks rose Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each gaining 0.4%.The iShares Biotechnology ETF (IBB) climbed 2%.In corporate news, McKesson (MCK) agreed to buy Precision Medicine Group for $2.25 billion as part of the drug distributor's efforts to boost its clinical research and commercialization services. McKesson shares rose 2.2%.Jazz Pharmaceuticals (JAZZ) shares gained 3.1% after the company said the US Food and Drug Administration approved two of its Ziihera-containing regimens to treat adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of cancer.Immatics (IMTX) shares climbed 5.4% after the company agreed to sell ordinary shares and pre-funded warrants in an underwritten offering expected to generate $150 million in gross proceeds.

$IMTX$JAZZ$MCK
Wire

Jazz Pharmaceuticals Says FDA Approved Ziihera Regimens for HER2-Positive Gastroesophageal Cancer

Jazz Pharmaceuticals (JAZZ) said Tuesday that the US Food and Drug Administration approved two of its Ziihera-containing regimens to treat adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of cancer.The two regimens are Ziihera plus Tevimbra and chemotherapy for all HER2-positive patients, and Ziihera plus chemotherapy alone for those with IHC 3+ disease, the company said.Jazz said that the approval was based on results from its Phase 3 HERIZON-GEA-01 trial, which showed significant improvements in progression-free survival and overall survival.Shares of the company were up 2.5% in early Tuesday trading.Price: $258.76, Change: $+4.29, Percent Change: +1.69%

$JAZZ
Wire

Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says

Jazz Pharmaceuticals' (JAZZ) recent acquisition of Actio Biosciences' KCNT1 epilepsy asset "makes sense" with a reasonable price tag and good synergy with its existing business, RBC Capital Markets said in a Monday note.According to the note, the deal focuses on a high unmet need in treating rare epilepsy, with the ABS-1230 drug phase 1/2 clinical trials evaluating efficacy in patients with KCNT-1-related mutation. Due to the severity of the particular disease, a launch will likely result in a rapid penetration of the market, with potential for $500 million revenue by 2035, RBC analysts said. They added that the regulatory approval process should be manageable.Due to the deal's synergies with Jazz's existing assets, the analysts forecast no need for additional overhead costs and only a modest increase of about $30 million in research and development expenses to run ongoing trials.Even with the transaction, Jazz continues to have strategic flexibility for further moves, on top of its resilient oxybate business and the growth of its Ziihera product, according to the note.RBC has an outperform rating on the stock, with a price target of $273.Price: $249.33, Change: $-7.19, Percent Change: -2.80%

$JAZZ
Insider Trading

Jazz Pharmaceuticals Insider Sold Shares Worth $1,517,880, According to a Recent SEC Filing

Bruce C Cozadd, Director, on August 03, 2026, sold 6,000 shares in Jazz Pharmaceuticals (JAZZ) for $1,517,880. Following the Form 4 filing with the SEC, Cozadd has control over a total of 360,682 ordinary shares of the company, with 360,682 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1232524/000119321026000018/xslF345X05/edgardoc.xml

$JAZZ
Wire

Jazz Pharmaceuticals Q2 Results Exceeded Expectations, With Growth Across Portfolio, RBC Says

Jazz Pharmaceuticals (JAZZ) Q2 results exceeded expectations on revenue growth, demonstrating strength across Epidiolex, oncology and sleep segments, RBC Capital Markets analysts said in a Monday note.While Jazz's spending increased in Q2, the investment is necessary to drive sustained revenue, with the possible near-term zanidatamab launch also expected to be a growth driver, RBC said.Jazz is likely in later stage label discussions with the Food and Drug Administration regarding the zanidatamab launch for the treatment of gastroesophageal adenocarcinoma, the analysts said.If approved, zanidatamab has the potential to generate about $1.5 billion in peak sales in gastroesophageal adenocarcinoma, RBC said.RBC retained an outperform rating on the stock and increased its price target to $273 from $258Price: $249.29, Change: $-2.29, Percent Change: -0.91%

$JAZZ
Wire

Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says

Jazz Pharmaceuticals (JAZZ) delivered a strong Q2 as Xywav continued to outperform despite generic competition, prompting another increase in the company's full-year outlook, Morgan Stanley said in a research note Tuesday.The investment firm said the increase reflects strong first hald execution and expected double-digit growth from Xywav and the combined epilepsy and oncology franchises.The company's management said the slower-than-expected uptake of high-sodium generic competitors was a key reason for raising full-year guidance and expressed increased confidence in Xywav's long-term competitive position.Morgan Stanley said Ziihera remains Jazz Pharmaceuticals' most important oncology growth driver. Management reiterated confidence ahead of the Aug. 25 PDUFA date for Ziihera as a first-line treatment for HER2-positive gastric and gastroesophageal adenocarcinoma and said interactions with the US FDA have been productive.The investment firm raised Jazz's full-year 2026 revenue estimate to $4.77 billion from $4.47 billion. It also increased non-GAAP EPS estimates to $25.14 for 2026 and $28.85 for 2027 from $24.99 and $27.28.Morgan Stanley has an overweight rating on Jazz Pharmaceuticals and raised its price target to $280 from $245.Price: $251.98, Change: $+0.40, Percent Change: +0.16%

$JAZZ
Wire

Jazz Pharmaceuticals Has Several Growth Options Beyond Marketed Drugs, RBC Says

Jazz Pharmaceuticals (JAZZ) has a number of options that could add meaningful growth over the coming years beyond the company's currently marketed drugs, RBC Capital Markets said in a Friday research note.Building on this, RBC favors the internal development of an orexin receptor agonist, although reviving development of its suvecaltamide essential-tremor treatment, entering the psychedelics space, or building on its brain-cancer business could also add value, according to the note.Pursuing an internal orexin program and expanding the glioma franchise would yield internal synergies, and the balance-sheet savings from developing an orexin program internally could be used to bolt on a glioma drug for relatively low cost, RBC said.Additionally, RBC said the relatively limited research-and-development investment required for some late-stage psychedelic programs could benefit Jazz Pharmaceuticals because it could allow for nearer-term revenue accretion.RBC reiterated its outperform rating and maintained its $258 price target on the company's stock.Price: $252.24, Change: $-6.14, Percent Change: -2.38%

$JAZZ
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Wire

Jazz Pharmaceuticals Investors Eye Ziihera Launch in GEA as Key Driver, UBS Says

Jazz Pharmaceuticals (JAZZ) is unlikely to see a meaningful Q2-driven stock reaction, with investors focused instead on the expected approval and launch of Ziihera in gastroesophageal adenocarcinoma, or GEA, as the key near-term catalyst, UBS said in a note Wednesday.The analysts said that while the stock has lagged the recent biotech rally, this is largely because gains have been concentrated in smaller-cap companies driven by mergers and acquisitions activity, and some investors had already expected National Comprehensive Cancer Network guideline inclusion for GEA, which has yet to occur."We note that Jazz stock outperformed in Q4 2025/Q1 2026, but we believe the Q2 update could have a marginal impact on the stock," they added.The company has more meaningful near-term upside from the expected approval and launch of Ziihera in GEA, with a PDUFA date of Aug. 25, according to the note.Longer term, additional value creation is expected from business development and pipeline expansion, as well as breast cancer topline data expected in late 2027 to early 2028. "Despite some erosion to the sleep franchise (generics), we believe the base business should remain stable as we approach GEA's launch," the analysts said.The analysts expect Q2 total revenue of $1.1 billion, broadly in line with consensus, and full-year 2026 revenue of $4.4 billion versus consensus of $4.5 billion. Q2 earnings per share are expected to be $6.29 versus the consensus of $6.19 and the prior estimate of $6.49.UBS has a buy rating and a $307 price target on Jazz Pharmaceuticals.Price: $241.42, Change: $+3.91, Percent Change: +1.65%

$JAZZ
Commodities

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Rates Announcement

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.7% in Wednesday's premarket activity, ahead of the highly anticipated interest rate announcement by the Federal Reserve at 2 pm ET.US stock futures were mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures slipping 0.1%, and Nasdaq futures gaining 0.6% before the start of regular trading.Mortgage applications fell by 3.8% in the week ended June 12 after a 10.8% increase in the previous week, as average 30-year fixed mortgage rates held steady, according to Mortgage Bankers Association data released Wednesday.US retail sales rose by 0.9% in May, a larger gain than the 0.6% increase expected in a survey compiled by Bloomberg as of 7:35 am ET and following the previous month's revised 0.4% gain.The pending home sales data for May and the business inventories data for April are both scheduled to be released at 10:00 am ET.Weekly petroleum stocks data are due to be released at 10:30 am ET.The Federal Reserve's 2 pm ET announcement will be followed by new Fed Chair Kevin Warsh's first press conference at 2:30 pm ET.In premarket action, bitcoin was down by 1.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.2% lower, Ether ETF (EETH) retreated by 2.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was inactive.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.1%. The Vanguard Health Care Index Fund (VHT) fell 0.2% and the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was 0.5% higher.AbCellera Biologics (ABCL) shares rose 2.4%, and Jazz Pharmaceuticals (JAZZ) stock was up 1.6% premarket after the companies signed a preclinical research collaboration, option, and license deal to discover and develop T-cell-engaging multispecific antibodies.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.3%, the Vanguard Industrials Index Fund (VIS) was up 0.1%, and the iShares US Industrials ETF (IYJ) was inactive.SpaceX (SPCX) stock was up more than 3% before the opening bell, following a 4.8% rise in Tuesday's session. Investor Michael Burry, known for calling the US housing collapse and the 2008 financial crisis, wrote in his newsletter on Tuesday that the company's put options remain too expensive.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 1.3%, and the iShares US Technology ETF (IYW) was up 0.8%, while the iShares Expanded Tech Sector ETF (IGM) was up 1.9%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 1.9% higher, while the iShares Semiconductor ETF (SOXX) rose by 2.7%.Nokia (NOK) shares were up 2.6% in premarket activity after the company said it will expand its advanced semiconductor test and packaging facilities in Allentown, Pennsylvania, to increase the manufacturing of photonic chips for artificial intelligence networks.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.6%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 1%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.2%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Stellantis (STLA) shares were up 1.9% pre-bell after Bloomberg reported, citing FIM-CISL labor union secretary general Ferdinando Uliano, that the company has pledged new investments in Italy, including 5 billion euros ($5.80 billion) in research and development by 2030 and the addition of engineering jobs.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated by 0.03%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% higher.Aegon (AEG) shares were down 0.8% pre-bell after gaining 1.5% at the prior close. The company said it has appointed Will Fuller as chief operating officer, effective Jan. 1, 2027.EnergyThe iShares US Energy ETF (IYE) was down 0.8%, while the State Street Energy Select Sector SPDR ETF (XLE) retreated by 0.1%.YPF (YPF) stock was down 0.1% before the opening bell, adding to the 2.6% loss at the previous close. Reuters reported that the company signed a letter of intent to explore collaborations in fast-charging networks and energy storage infrastructure.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.9% to $76.73 per barrel on the New York Mercantile Exchange. Natural gas retreated by 0.7% to $3.22 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 0.4%, while the United States Natural Gas Fund (UNG) was 1.1% lower.Gold futures for July were slightly lower to $4,352.50 an ounce on the Comex. Silver futures gained 0.1% to $70.58 an ounce. SPDR Gold Shares (GLD) declined by 0.01%, and the iShares Silver Trust (SLV) was 0.3% lower.

Dow JonesNasdaq CompositeS&P 500$ABCL$AEG$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$JAZZ$NOK$PMR$QQQ$RTH$SLV$SOXX$SPCX$SPY$STLA$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD$YPF
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.1% higher.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Shares of Novo Nordisk were up more than 3% pre-bell.uniQure (QURE) stock was up more than 66% after the company said it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Jazz Pharmaceuticals (JAZZ) and AbCellera Biologics (ABCL) signed a preclinical research collaboration, option and license deal to discover and develop T-cell engaging multispecific antibodies, the companies said. Shares of AbCellera Biologics were up more than 2% and Jazz Pharmaceuticals stock was over 1% higher premarket.

$ABCL$IBB$JAZZ$NVO$QURE$XLP
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 1%.AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer. AstraZeneca shares were declining 1.6%.Jazz Pharmaceuticals (JAZZ) shares fell 1.2% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped past 7%.

$AVTX$AZN$JAZZ$MRK
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks edged lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing about 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.3% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped 6%.Cogent Biosciences (COGT) said Bezuclastinib showed "rapid and deep" clinical benefit in advanced systemic mastocytosis patientsfollowing detailed and updated trial results. Shares rose 1.6%.

$AVTX$COGT$JAZZ
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index decreasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.6% after it said Friday that a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet the primary overall survival endpoint, whether used alone or in combination with irinotecan, versus the investigator's choice of chemotherapy.

$JAZZ

Showing 1-20 of 25

Track with the FINWIRES app suite

FolioX
FolioX
Track JAZZ in your portfolio
WheelAI
WheelAI
Analyze JAZZ options with the wheel strategy
StockInsider
StockInsider
See market sentiment on JAZZ